CalciMedica Inc. (CALC) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

CalciMedica Inc. (CALC)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

3.27

0.35 (11.99%)

At close: Jan 14, 2025, 3:57 PM

3.01

-7.95%

After-hours Jan 14, 2025, 03:58 PM EST

undefined% (undefined)

Bid	2.65
Market Cap	44.09M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.11
PE Ratio (ttm)	-2.95
Forward PE	n/a
Analyst	Buy

Ask	3.61
Volume	23,765
Avg. Volume (20D)	62,375
Open	3.01
Previous Close	2.92
Day's Range	2.95 - 3.27
52-Week Range	2.05 - 8.38
Beta	undefined

About CALC

CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC c...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 14, 2023

Employees 13

Stock Exchange NASDAQ

Ticker Symbol CALC

Website https://www.calcimedica.com

Analyst Forecast

According to 4 analyst ratings, the average rating for CALC stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 450.46% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

2 months ago · Source

-22.92%

CalciMedica shares are trading lower after the com... Unlock content with Pro Subscription

6 months ago · Source

-32.4%

CalciMedica shares are trading lower. The stock initially gained after the company announced topline data from its Phase 2b CARPO trial of Auxora in acute pancreatitis but has reversed.

News

5 months ago · zacks.com

Does CalciMedica Inc. (CALC) Have the Potential to Rally 232.3% as Wall Street Analysts Expect?

The consensus price target hints at a 232.3% upside potential for CalciMedica Inc. (CALC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...

7 months ago · investorplace.com

3 Massively Undervalued 10-Bagger Stocks to Buy

If you're on the lookout for the best undervalued stocks to buy now, look no further. Savvy investors are always looking for cheap businesses with substantial growth potential.

11 months ago · 24/7 Wall Street

Huge Insider Buys From Warren Buffett, Jack Ma, Carlos Slim and More

Overall, the number of notable insider purchases may have dwindled with the earnings-reporting season in full swing, but there were still some huge, headline-making buys in the past week or so.